Exenatide oral - Oramed

Drug Profile

Exenatide oral - Oramed

Alternative Names: Oral exenatide capsules - Oramed; ORMD-0901; ORMD-901

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 29 Nov 2016 Positive safety data from a phase Ib trial in Type-2 diabetes mellitus released by Oramed
  • 29 Nov 2016 Oramed completes a phase Ib trial in Type-2 diabetes mellitus in Israel
  • 29 Nov 2016 Oramed plans a phase IIb trial for Type-2 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top